A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2023-08-28
Target enrollment:
Participant gender:
Summary
DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour
activity of T-DXd in combination with other therapies in patients with Metastatic HER2-low
Advanced or Metastatic Breast Cancer